Core Viewpoint - Caring Brands Inc. has announced the issuance of two new U.S. patents that enhance its intellectual property portfolio for the Hair Enzyme Booster product, aimed at improving hair loss treatments [1][2][3] Patent Issuance - The patents, granted in January 2026, focus on technologies that increase sulfotransferase enzyme activity, which is crucial for the effectiveness of topical hair loss treatments [2] - These patents provide exclusive protection for mechanisms central to the Hair Enzyme Booster, which is generating revenue through direct sales in the U.S. and international licensing [2] Company Strategy - The CEO of Caring Brands highlighted that the patents represent a significant milestone, validating the scientific basis of the Hair Enzyme Booster technology and enhancing the company's competitive position [3] - The company is committed to developing, protecting, and commercializing proprietary technologies with substantial clinical and commercial potential, with plans for further updates on product development and distribution [3] Product Portfolio - Caring Brands has a growing portfolio of patented and clinically validated products for skin and hair growth, with plans to launch five additional products over the next two years [4] - Current revenue is generated from the Hair Enzyme Booster and Photocil, with additional product opportunities including CB-101 for eczema and NoStingz sunscreen [4]

Core Insights - Caring Brands Inc. has entered into an exclusive worldwide license agreement with Itonis Inc. to manufacture, market, and distribute Emesyl, an OTC nausea relief product, which provides Caring Brands with full commercialization rights [1][2] Company Overview - Caring Brands Inc. has a growing portfolio of unique, patented, and clinically validated products for skin and hair growth, with plans to launch a total of 5 products over the next 2 years [5] - The company has a successful track record in strategic acquisitions, rapid product development, intellectual property development, and product licensing [5] Market Context - The global market for nausea treatment and related therapies is projected to exceed USD 6.23 billion in 2025, highlighting the commercial potential for the Emesyl license [3] Agreement Details - Under the agreement, Caring Brands will handle product manufacturing, marketing, sales strategy, and global distribution, while Itonis will provide necessary technical and historical sales information [2] - The agreement includes a royalty structure based on future net sales and the potential for Caring Brands to earn equity in Itonis tied to revenue milestones [4]